Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: FNC, EGV, TRI

The Department of Precision Medicine of Maastricht University Receives 920K? from the European Commission to Further Develop Their Work on Artificial Intelligence Tools for COVID-19 Patients


MAASTRICHT, Netherlands, May 13, 2020 /PRNewswire/ -- The Department of Precision Medicine at Maastricht University (The Netherlands) announced today the release of their AI tool for COVID-19 patient triage, the same week that they received 920K? from the European Commission for the DRAGON project (link: information on the grant).

The D-Lab group of the Dpt of Precision Medicine is developing a personalized medicine platform to enable risk assessment of COVID-19 patients. The models, made by the group or published elsewhere, are available world-wide on their new platform https://covid19risk.ai

"We are excited to be participating in the global fight against the COVID-19 pandemic with our Decision Support System for Risk Assessment of COVID-19 patients. We have repurposed our AI methods, usually applied to oncology questions, to the COVID-19 pandemic," said Prof. Philippe Lambin, Department Head. The platform can integrate various types of medical data available as well as assess the risk of severe disease that requires mechanical ventilation.

"We also have simple models to identify vulnerable patients that should follow a strict lockdown, which include, for example, not doing their groceries themselves if they are over the age of 64 and have high blood pressure," said Dr. Avishek Chatterjee.

The recently funded European project DRAGON will achieve a patient empowerment centred decision support system that will enable multiple stakeholders to participate in improved and more rapid diagnosis, as well as the potential of precision medicine for accelerated development of new therapies.

Dr. Cary Oberije, head of the Virtual Trial Unit of the Dpt of Precision Medicine, added: "One of our missions will be to coordinate an international prospective biomarker trial on COVID-19 patients. We want to understand this virus better and use this knowledge for future outbreaks, also for other viruses."

The entire effort will be supported by the deployment of a federated machine learning system, a technology developed in Maastricht by Prof Lambin's group, that will allow for the GDPR compliant use of multinational data resources.

About the Dpt of Precision Medicine

The Department of Precision Medicine is a disease-agnostic AI department with an international group of researchers at Maastricht University. For more information visit www.precisionmedicinemaastricht.eu.

 

SOURCE Dpt of Precision Medicine, Maastricht University


These press releases may also interest you

at 18:00
The "Prepaid Cards - Global Strategic Business Report" has been added to  ResearchAndMarkets.com's offering. The global market for Prepaid Cards estimated at US$2 Trillion in the year 2023, is projected to reach a revised size of US$4.1 Trillion by...

at 17:25
Five years after the transformational Merger with Randgold Resources, Barrick Gold Corporation has been restructured and repurposed as a modern mining business with a constantly replenished, global asset base of peerless quality, managed by a team...

at 17:15
The "Australia Plastic Packaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029" report has been added to  ResearchAndMarkets.com's offering. The Australia Plastic Packaging Market size estimated at USD 2.79...

at 17:05
Trinity Capital Inc.  ("Trinity" or the "Company"), a leading provider of diversified financial solutions to growth stage companies, today announced an adjustment to the conversion rate of its 6.00% Convertible Notes due 2025 (the "Convertible...

at 16:40
Vista Outdoor Inc. ("Vista Outdoor", "we", "us" or "our") and Czechoslovak Group a.s. ("CSG") announced today that they have voluntarily withdrawn and re-filed their joint voluntary notice to the Committee on Foreign Investment in the United States...

at 16:35
The Board of Directors of Chimera Investment Corporation announced the declaration of its first quarter cash dividend of $0.11 per common share. The dividend is payable April 30, 2024 to common stockholders of record on April 8, 2024. The ex-dividend...



News published on and distributed by: